Saving money on the PBS: Ranibizumab or Bevacizumab for Neovascular Macular Degeneration? by Harvey, K et al.
EDITORIALSSaving money on the PBS: ranibizumab or bevacizumab for 
neovascular macular degeneration?
Ken J Harvey, Richard O Day, William G Campbell and Wendy LipworthThe Medical Journal of Australia ISSN: 0025-
729X 6 June 2011 194 11 567-568
©The Medical Journal of Australia 2011
www.mja.com.au
Editorials
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Ranibizumab (Lucentis), developed by Genentech and marketed
by Novartis in Australia, is currently the only drug approved by
the Therapeutic Goods Administration (TGA) and available on the
PBS to treat wet AMD. It is administered as an intravitreal
injection, usually 4–8-weekly, for 12 to 18 months or longer. The
PBS-listed price of each injection is $1967. Ranibizumab is the
antigen-binding fragment of a recombinant, humanised, mono-
clonal antibody that binds to vascular endothelial growth factor A
(VEGF-A), the cytokine primarily responsible for blood vessel
growth. The inhibition of VEGF-A reduces the permeability and
growth of the neovascular vessels. Blindness is prevented in most
patients, and the majority of treated patients go on to have some
improvement in vision.3-5
Bevacizumab (Avastin) is an anti-VEGF-A humanised, mono-
clonal antibody (also developed by Genentech, and marketed in
Australia by Roche; Genentech is a wholly owned subsidiary of
Roche) that has been approved by the TGA for the systemic
treatment of certain cancers. It was successfully used “off-label” for
the treatment of wet AMD before ranibizumab became available,
but has also been used to some degree since the availability of
ranibizumab, especially in the United States, where patients bear
more of the costs of drugs.5-7 It is prepared for ophthalmic use in a
sterile pharmacy by taking a dose used in chemotherapy and
splitting it for use in treating wet AMD for up to 25 patients. The
cost of its off-label use has been significantly less than that of
ranibizumab (around a 40th of the cost, at $50 per dose).
Ranibizumab received PBS listing for use in treating wet AMD in
2007 and has since largely replaced bevacizumab for the treatment
of AMD in Australia. Although therapy with ranibizumab has been
successful, its PBS listing has come at great expense, costing
taxpayers $237 million in 2010 (second only to atorvastatin and
rosuvastatin).
It is consistent with many of the principles of quality use of
medicines (QUM), outlined in the National Medicines Policy,8,9 for
ophthalmologists to select a PBS-listed therapy that has been
demonstrated to be safe and effective. But advocates of QUM also
emphasise the importance of choosing medicines that are cost-
effective for individuals and the community.
A recent study by the US National Eye Institute10 has raised the
question of whether use of ranibizumab can be justified economi-
cally. The study compared bevacizumab and ranibizumab for the
treatment of wet AMD, administered either monthly or as needed,
in 1208 randomly assigned patients. At 1 year, bevacizumab and
ranibizumab had equivalent effects on visual acuity, when adminis-
tered according to the same schedule. Ranibizumab given as
needed, with monthly evaluation, had effects on vision that were
equivalent to those of ranibizumab administered monthly. The
comparison between bevacizumab as needed and monthly bevac-
izumab was inconclusive. Differences in rates of serious adverse
events were higher with bevacizumab but did not reach statistical
significance, and require further study. Results from the second
year of this study and from other comparative trials and experien-
tial databases will provide additional information.
Despite this new information having come to light, in Australia
there is little motivation for clinicians, the pharmaceutical compa-
nies involved, or government bodies to pursue a broader economic
agenda. There is no incentive for Australian ophthalmologists or
patients to use bevacizumab off-label because the price to the
patient for the PBS-listed ranibizumab is only that of the copay-
ment, and the costs for the ophthalmologist visits are the same.
There is little incentive for the sponsor of bevacizumab (Roche) to
seek a new indication (wet AMD) for this drug — first from the
TGA and then from PBAC — because of the substantial costs
involved and the doubtful rewards. Also, the relationships between
the companies involved appear to militate against moves that
might change the present situation. Applications to both the TGA
and PBAC are now fully cost-recovered by charges levied on the
sponsor of the drug — a unique situation among equivalent
developed countries. This provides a considerable disincentive for
applications that are primarily in the public interest. While charges
can be reduced or eliminated for so-called orphan drugs, this
provision would not apply in this case because ranibizumab is
currently available and patent-protected.11 And although it has
been suggested that a third party, such as a Royal College, might
sponsor an application to the TGA and PBAC in the public
interest, this concept has foundered because the sponsor is also
responsible for product liability.
This leaves us with the question: what policy options might
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First, the drug committees and administrations of public hospi-
tals with significant eye services could recommend off-label use of
bevacizumab for AMD, in the light of the National Eye Institute
study. Currently, in New South Wales public hospitals, there is no
PBS access to ranibizumab. This would also accommodate public
patients unable to pay for private ophthalmologist visits. Given the
issues with bevacizumab of dose preparation, sterility and shelf
life, combining services for efficiency and geographical coverage
would make sense, as would amalgamating public clinics that
already use bevacizumab off-label for other related indications (eg,
diabetic retinopathy).
Second, the government could consider ways in which it could
withdraw the PBS listing for ranibizumab for the treatment of wet
AMD, on the grounds that treatment with bevacizumab in public
eye hospitals is likely to be more cost-effective. This is likely to be
problematic for several reasons: the limited capacity of the public
sector to provide this treatment; opposition by ophthalmologists
operating privately and those who deliver public services; and
opposition from the sponsor.
Third, the government could negotiate with Novartis to reduce
the cost of ranibizumab, or with Roche to apply to have bevacizu-
mab approved and listed for use in treating AMD. It should be
noted that the effort needed to register, list and distribute medi-
cines internationally and in Australia should be considered in
these negotiations, but the cost differential now extant in the light
of the National Eye Institute study results is no longer defensible.
Finally, the government could accept that it is the only body
with the responsibility and capability of acting in the public
interest in these matters. The Minister for Health and Ageing could
ask the TGA and PBAC to consider listing bevacizumab for
neovascular AMD in the public interest, perhaps with a temporary
or provisional licence pending accumulation of more data, with
the government accepting any liability that may accrue.
Although the challenges of achieving an equitable solution to
this problem are considerable, the significance to the PBS budget
and subsequently for analogous situations is now a strong incen-
tive for action.
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